COMMUNIQUÉS West-GlobeNewswire

Progyny, Inc. Executives to Participate in Upcoming Investor Conferences
06/03/2026
NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced that several members of its leadership team will participate in [...]
Transforming Healthcare Ltd Founder Dr. Pietro Emanuele Garbelli Wins BREW Readers' Book of the Month for 'The Doctor's Future'
06/03/2026
Transforming Healthcare Ltd founder recognised by BREW and profiled by The World’s Best on accountable AI, robotics, and the future of medicine London, GREATER LONDON, March 06, 2026 (GLOBE NEWSWIRE) -- London, UK — 6 [...]
BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor
06/03/2026
BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has high selectivity over HRAS and NRAS, and displays strong activity in KRAS mutant preclinical [...]
Holland Bloorview Kids Rehabilitation Hospital launches its 10th annual Capes for Kids fundraiser
06/03/2026
Calling all fundraisers to don their capes from March 6-13 to support children with disabilities Toronto, March 06, 2026 (GLOBE NEWSWIRE) -- Holland Bloorview Kids Rehabilitation Hospital (Holland Bloorview) kicks off [...]
SleepZee Anti-Snoring Mouthpiece Consumer Report: 2026 Analysis of Mandibular Advancement Device Research, Snoring Reduction Claims, and What Buyers Should Verify
06/03/2026
A 2026 informational consumer research report examining SleepZee anti-snoring mouthpiece mandibular advancement claims, boil-and-bite snoring mouth guard effectiveness research, company Terms of Service disclosures, [...]
Nika Pharmaceuticals, Inc. (NIKA) Signed a Consultancy Agreement with MD Global Partners LLC
06/03/2026
HENDERSON, Nev., March 06, 2026 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB: NIKA ) announces that it has signed a consultancy agreement with MD Global Partners LLC, a leading Manhattan-based investment bank. [...]
Informations relatives au nombre total de droits de vote et d’actions composant le capital
06/03/2026
Nantes, le 6 mars 2026 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement général de l’AMF, OSE Immunotherapeutics (ISIN : FR0012127173 ; Mnémo : OSE), société intégrée de [...]
EssilorLuxottica: Mise à disposition du Document d’enregistrement universel 2025
06/03/2026
Mise à disposition du Document d’enregistrement universel 2025 Paris, France (6 mars 2026) – EssilorLuxottica annonce la mise à disposition de son Document d’enregistrement universel 2025 dans les conditions requises [...]
EssilorLuxottica: 2025 Universal Registration Document filed
06/03/2026
2025 Universal Registration Document filed Paris, France (6 March 2026) – EssilorLuxottica announces the availability of its 2025 Universal Registration Document, in accordance with applicable regulation. The French [...]
VALNEVA Déclaration d’actions et de droits de vote : 28 février 2026
06/03/2026
VALNEVA Déclaration d’actions et de droits de vote 28 février 2026 __________________________________________________________________________________________ Dénomination sociale : VALNEVA Adresse du siège social : Îlot [...]
VALNEVA Declaration of shares and voting rights: February 28, 2026
06/03/2026
VALNEVA Declaration of shares and voting rights February 28, 2026 __________________________________________________________________________________________ Company name: VALNEVA Registered office: Îlot Saint-Joseph [...]
Tangram Therapeutics annonce l’administration de la première dose à un participant dans le cadre de l’essai RESTORE-MASH de phase I/II portant sur le TGM-312, un nouveau médicament expérimental à base d’ARNi
06/03/2026
L’essai RESTORE-MASH de phase I/II évaluera la sécurité, la pharmacocinétique et la pharmacodynamique du TGM-312 chez des volontaires en bonne santé et des patients atteints de MASH Les premières données sont attendues [...]
Bluejay Diagnostics Provides Corporate Update and 2026 Strategic Outlook
06/03/2026
ACTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid near-patient tests to improve patient outcomes in [...]
Verano to Report Fourth Quarter and 2025 Full Year Financial Results on March 12th, 2026
06/03/2026
CHICAGO, March 06, 2026 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced that it plans to release financial [...]
AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update
06/03/2026
Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End‑of‑Phase 2 meeting with the U.S. Food and Drug Administration On-track for VLS-01 [...]
Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
06/03/2026
JADE101 Phase 1 healthy volunteer interim data expected in the second quarter of 2026; Phase 2 clinical trial in patients with IgA nephropathy expected to begin mid-2026 with preliminary data anticipated in 2027 JADE201 [...]
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
06/03/2026
NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of [...]
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/03/2026
SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today [...]
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
06/03/2026
- 64% overall survival observed at 12 months in ongoing Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients, well above the standard of care benchmark from GnP of 35% overall survival; On [...]

Pages